

**ValiRx plc
(the “Company”)**

**Placing Summary
&
Total Voting Rights**

Placing Summary

The Company is pleased to announce that the recent placing of ordinary shares of 1p each in the Company (“Ordinary Shares”) raised, in aggregate, £978,999.98, before expenses, via the placing of 94,566,665 Ordinary Shares at a price of either 1p per share or 1.2p per share (the “Placing”). The net proceeds from the Placing will enable the Company to progress the CE marking process for the market launch of its Human Papilloma Virus diagnostic screening kit for cervical cancer, which the directors believe is a rapidly growing market, and to advance its therapeutic products to the start of in man clinical trials.

Total Voting Rights

For the purposes of the transitional provisions of the Financial Services Authority’s Disclosure and Transparency Rules, the total number of Ordinary Shares in issue as at the date of this notice is 153,145,030 with each share carrying the right to one vote.

There are no shares held in treasury.

Therefore, the total number of voting rights in the Company is 153,145,030.

The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure and Transparency Rules.

For more information please contact:

ValiRx plc
Dr. Satu Vainikka

Tel: +44 (0) 20 3008 4416

WH Ireland Limited
Adrian Kirk

Tel: +44 (0) 161 832 2174